Europe PCR-based Infectious Diseases Market - Industry Trends and Forecast to 2033

Description

List of Tables

The Europe PCR-based infectious diseases market is expected to reach USD 1,829,817.21 thousand by 2031 from USD 1,131,805.47 thousand in 2023, growing with a CAGR of 6.5% in the forecast period of 2024 to 2031.

Market Segmentation

Europe PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, and Rest of Europe) - Industry Trends and Forecast to 2031

Overview of Europe PCR-based Infectious Diseases Market Dynamics

Driver
Increasing PCR-based research activities
Restraint
High cost of PCR test services
Opportunity
Disease surveillance for early detection and monitoring of infectious diseases

Market Players

Some of the major market players operating in the Europe PCR-based infectious diseases market are:

DNA Labs India
DrSafeHands
Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
Max Lab
MicroGen Diagnostics
pathlab
The Washington Travel Clinic
Clarewell Clinics
AZOVA
One Life Home Health Care Center
LalPathLabs

1 INTRODUCTION 44

1.1 OBJECTIVES OF THE STUDY 44
1.2 MARKET DEFINITION 44
1.3 OVERVIEW OF EUROPE PCR-BASED INFECTIOUS DISEASES MARKET 44
1.4 CURRENCY AND PRICING 45
1.5 LIMITATIONS 46
1.6 MARKETS COVERED 46

2 MARKET SEGMENTATION 49

2.1 MARKETS COVERED 49
2.2 GEOGRAPHICAL SCOPE 50
2.3 YEARS CONSIDERED FOR THE STUDY 51
2.4 DBMR TRIPOD DATA VALIDATION MODEL 52
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.6 MULTIVARIATE MODELLING 56
2.7 MARKET APPLICATION COVERAGE GRID 57
2.8 TEST TYPE LIFELINE CURVE 58
2.9 DBMR MARKET POSITION GRID 59
2.10 VENDOR SHARE ANALYSIS 60
2.11 SECONDARY SOURCES 61
2.12 ASSUMPTIONS 61

3 EXECUTIVE SUMMARY 62

4 PREMIUM INSIGHTS 65

4.1 PESTEL ANALYSIS 66
4.2 PORTER'S FIVE FORCES 67

5 MARKET OVERVIEW 68

5.1 DRIVERS 70
- 5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 70
- 5.1.2 RISING CASES OF INFECTIOUS DISEASES 70
- 5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 71
5.2 RESTRAINTS 72
- 5.2.1 HIGH COST OF PCR TEST SERVICES 72
- 5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 73
5.3 OPPORTUNITIES 74
- 5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 74
- 5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 74
- 5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 75
5.4 CHALLENGES 76
- 5.4.1 DATA SECURITY AND PRIVACY CONCERNS 76
- 5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 76

6 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 78

6.1 OVERVIEW 79
6.2 TUBERCULOSIS PCR TEST 85
6.3 HEPATITIS PCR TEST 85
- 6.3.1 HEPATITIS C PCR TEST 86
- 6.3.2 HEPATITIS B PCR TEST 86
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 87
6.5 INFLUENZA PCR TEST 87
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 88
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 88
6.8 GONORRHEA PCR TEST 89
6.9 SALMONELLOSIS PCR TEST 89
6.10 ROTAVIRUS PCR TEST 90
6.11 BORDETELLA PCR TEST 90
6.12 H. PYLORI PCR TEST 91
6.13 SARS (COVID-19) PCR TEST 91
6.14 NOROVIRUS PCR TEST 92
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 92
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 93
6.17 ENTEROCOCCUS PCR TEST 93
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 94
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 94
6.20 OTHERS PCR TEST 95

7 EUROPE PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 96

7.1 OVERVIEW 97
7.2 VIRAL INFECTION 100
- 7.2.1 SARS (COVID-19) INFECTION 100
- 7.2.2 ROTAVIRUS INFECTION 100
- 7.2.3 NOROVIRUS INFECTION 100
- 7.2.4 OTHERS 101
7.3 RESPIRATORY TRACT INFECTION 101
- 7.3.1 INFLUENZA 101
- 7.3.2 TUBERCULOSIS 101
- 7.3.3 BORDETELLA 102
7.4 SEXUALLY TRANSMITTED INFECTION 102
- 7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 103
- 7.4.2 GONORRHEA 103
- 7.4.3 HEAPTITIS 103
- 7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 103
- 7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 103
- 7.4.6 MYCOPLASMA GENITALIUM (MG) 103
- 7.4.7 OTHERS 103
7.5 HOSPITAL ACQUIRED INFECTIONS 104
- 7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 104
- 7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 104
- 7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 105
- 7.5.4 OTHERS 105
7.6 OTHER INFECTIONS 105
- 7.6.1 SALMONELLOSIS 105
- 7.6.2 H. PYLORI 106
- 7.6.3 ENTEROCOCCUS INFECTIONS 106
- 7.6.4 OTHERS 106

8 EUROPE PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 107

8.1 OVERVIEW 108
8.2 VIRAL 111
8.3 BACTERIAL 111
8.4 FUNGAL 112
8.5 PROTOZOA 112
8.6 OTHERS 113

9 EUROPE PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 114

9.1 OVERVIEW 115
9.2 RT PCR 118
9.3 MULTIPLEX PCR 118
9.4 OTHERS 119

10 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 120

10.1 OVERVIEW 121
10.2 GERIATRIC 124
10.3 PEDIATRIC 124
10.4 ADULTS 125

11 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 126

11.1 OVERVIEW 127
11.2 LABORATORY BASED TESTING 130
11.3 POINT OF CARE TESTING 130

12 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 131

12.1 OVERVIEW 132
12.2 DIAGNOSTIC CENTERS 135
12.3 HOSPITAL 135
12.4 CLINICS 136
12.5 COMMUNITY HEALTH CENTERS 136
12.6 ACADEMIC AND RESEARCH INSTITUTES 137
12.7 HOME HEALTHCARE 137
12.8 OTHERS 138

13 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 139

13.1 EUROPE 142
- 13.1.1 GERMANY 151
- 13.1.2 FRANCE 159
- 13.1.3 U.K. 167
- 13.1.4 ITALY 175
- 13.1.5 RUSSIA 183
- 13.1.6 SPAIN 191
- 13.1.7 TURKEY 199
- 13.1.8 NETHERLANDS 207
- 13.1.9 SWITZERLAND 215
- 13.1.10 BELGIUM 223
- 13.1.11 HUNGARY 231
- 13.1.12 REST OF EUROPE 239

14 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 242

14.1 COMPANY SHARE ANALYSIS: EUROPE 242

15 SWOT ANALYSIS 243

16 COMPANY PROFILE 244

16.1 MICROGEN DIAGNOSTICS 244
- 16.1.1 COMPANY SNAPSHOT 244
- 16.1.2 SERVICE PORTFOLIO 244
- 16.1.3 RECENT DEVELOPMENTS 245
16.2 MAX LAB 246
- 16.2.1 COMPANY SNAPSHOT 246
- 16.2.2 SERVICE PORTFOLIO 246
16.3 DNA LABS INDIA 248
- 16.3.1 COMPANY SNAPSHOT 248
- 16.3.2 SERVICE PORTFOLIO 248
- 16.3.3 RECENT DEVELOPMENT 249
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD. 250
- 16.4.1 COMPANY SNAPSHOT 250
- 16.4.2 SERVICE PORTFOLIO 250
- 16.4.3 RECENT DEVELOPMENT 251
16.5 LALPATHLABS 252
- 16.5.1 COMPANY SNAPSHOT 252
- 16.5.2 REVENUE ANALYSIS 252
- 16.5.3 PRODUCT PORTFOLIO 253
- 16.5.4 RECENT DEVELOPMENTS 253
16.6 AZOVA 254
- 16.6.1 COMPANY SNAPSHOT 254
- 16.6.2 PRODUCT PORTFOLIO 254
- 16.6.3 RECENT DEVELOPMENTS 254
16.7 CLAREWELL CLINICS 255
- 16.7.1 COMPANY SNAPSHOT 255
- 16.7.2 PRODUCT DESCRIPTION 255
- 16.7.3 RECENT DEVELOPMENTS 255
16.8 DRSAFEHANDS 256
- 16.8.1 COMPANY SNAPSHOT 256
- 16.8.2 SERVICE PORTFOLIO 256
- 16.8.3 RECENT DEVELOPMENT 256
16.9 ONE LIFE HOME HEALTH CARE CENTER 257
- 16.9.1 COMPANY SNAPSHOT 257
- 16.9.2 PRODUCT DESCRIPTION 257
- 16.9.3 RECENT DEVELOPMENTS 257
16.10 PATHLAB 258
- 16.10.1 COMPANY SNAPSHOT 258
- 16.10.2 SERVICE PORTFOLIO 258
- 16.10.3 RECENT DEVELOPMENT 258
16.11 THE WASHINGTON TRAVEL CLINIC 259
- 16.11.1 COMPANY SNAPSHOT 259
- 16.11.2 SERVICE PORTFOLIO 259
- 16.11.3 RECENT DEVELOPMENT 260

17 QUESTIONNAIRE 261

18 RELATED REPORTS 265

LIST OF TABLES

TABLE 1 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 61
TABLE 2 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 62
TABLE 3 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 63
TABLE 4 EUROPE TUBERCULOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 64
TABLE 5 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 64
TABLE 6 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 65
TABLE 7 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 65
TABLE 8 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 65
TABLE 9 EUROPE HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 66
TABLE 10 EUROPE INFLUENZA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 66
TABLE 11 EUROPE HUMAN PAPILLOMAVIRUS (HPV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 67
TABLE 12 EUROPE CHLAMYDIA TRACHOMATIS GENITAL PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 67
TABLE 13 EUROPE GONORRHEA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 68
TABLE 14 EUROPE SALMONELLOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 68
TABLE 15 EUROPE ROTAVIRUS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 69
TABLE 16 EUROPE BORDETELLA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 69
TABLE 17 EUROPE H. PYLORI PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 70
TABLE 18 EUROPE SARS (COVID-19) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 70
TABLE 19 EUROPE NOROVIRUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 71
TABLE 20 EUROPE C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 71
TABLE 21 EUROPE CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 72
TABLE 22 EUROPE ENTEROCOCCUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 72
TABLE 23 EUROPE MYCOPLASMA GENITALIUM (MG) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 73
TABLE 24 EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 73
TABLE 25 EUROPE OTHERS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 74
TABLE 26 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 78
TABLE 27 EUROPE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 79
TABLE 28 EUROPE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 79
TABLE 29 EUROPE RESPIRATORY TRACT INFECTION IN PCR-BASED INFFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 80
TABLE 30 EUROPE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 80
TABLE 31 EUROPE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 81
TABLE 32 EUROPE SEXUALLY TRANSMITTED INFECTION IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 81
TABLE 33 EUROPE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 83
TABLE 34 EUROPE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 83
TABLE 35 EUROPE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 84
TABLE 36 EUROPE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 84
TABLE 37 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 89
TABLE 38 EUROPE VIRAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 90
TABLE 39 EUROPE BACTERIAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 90
TABLE 40 EUROPE FUNGAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
TABLE 41 EUROPE PROTOZOA IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
TABLE 42 EUROPE OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 92
TABLE 43 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 96
TABLE 44 EUROPE RT PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
TABLE 45 EUROPE MULTIPLEX PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
TABLE 46 EUROPE OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 98
TABLE 47 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 102
TABLE 48 EUROPE GERIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 103
TABLE 49 EUROPE PEDIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 103
TABLE 50 EUROPE ADULTS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 104
TABLE 51 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 108
TABLE 52 EUROPE LABORATORY BASED TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 109
TABLE 53 EUROPE POINT OF CARE TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 109
TABLE 54 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER, 2022-2031 (USD THOUSAND) 113
TABLE 55 EUROPE DIAGNOSTIC CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
TABLE 56 EUROPE HOSPITAL IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
TABLE 57 EUROPE CLINICS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 115
TABLE 58 EUROPE COMMUNITY HEALTH CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 115
TABLE 59 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 116
TABLE 60 EUROPE HOME HEALTHCARE IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 116
TABLE 61 EUROPE OTHERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 117
TABLE 62 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 121
TABLE 63 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 122
TABLE 64 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 123
TABLE 65 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 124
TABLE 66 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 125
TABLE 67 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 125
TABLE 68 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 125
TABLE 69 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 125
TABLE 70 EUROPE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 126
TABLE 71 EUROPE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 126
TABLE 72 EUROPE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 127
TABLE 73 EUROPE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 127
TABLE 74 EUROPE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 128
TABLE 75 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 128
TABLE 76 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 128
TABLE 77 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 129
TABLE 78 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 129
TABLE 79 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 129
TABLE 80 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 130
TABLE 81 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 131
TABLE 82 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 132
TABLE 83 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 133
TABLE 84 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 133
TABLE 85 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 133
TABLE 86 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 133
TABLE 87 GERMANY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 134
TABLE 88 GERMANY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 134
TABLE 89 GERMANY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 135
TABLE 90 GERMANY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 135
TABLE 91 GERMANY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 136
TABLE 92 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 136
TABLE 93 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 136
TABLE 94 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 137
TABLE 95 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 137
TABLE 96 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 137
TABLE 97 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 138
TABLE 98 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 139
TABLE 99 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 140
TABLE 100 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 141
TABLE 101 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 141
TABLE 102 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 141
TABLE 103 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 141
TABLE 104 FRANCE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 142
TABLE 105 FRANCE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 142
TABLE 106 FRANCE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 143
TABLE 107 FRANCE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 143
TABLE 108 FRANCE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 144
TABLE 109 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 144
TABLE 110 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 144
TABLE 111 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 145
TABLE 112 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 145
TABLE 113 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 145
TABLE 114 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 146
TABLE 115 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 147
TABLE 116 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 148
TABLE 117 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 149
TABLE 118 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 149
TABLE 119 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 149
TABLE 120 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 149
TABLE 121 U.K. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 150
TABLE 122 U.K. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 150
TABLE 123 U.K. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 151
TABLE 124 U.K. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 151
TABLE 125 U.K. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 152
TABLE 126 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 152
TABLE 127 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 152
TABLE 128 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 153
TABLE 129 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 153
TABLE 130 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 153
TABLE 131 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 154
TABLE 132 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 155
TABLE 133 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 156
TABLE 134 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 157
TABLE 135 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 157
TABLE 136 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 157
TABLE 137 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 157
TABLE 138 ITALY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 158
TABLE 139 ITALY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 158
TABLE 140 ITALY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 159
TABLE 141 ITALY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 159
TABLE 142 ITALY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 160
TABLE 143 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 160
TABLE 144 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 160
TABLE 145 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 161
TABLE 146 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 161
TABLE 147 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 161
TABLE 148 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 162
TABLE 149 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 163
TABLE 150 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 164
TABLE 151 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 165
TABLE 152 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 165
TABLE 153 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 165
TABLE 154 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 165
TABLE 155 RUSSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 166
TABLE 156 RUSSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 166
TABLE 157 RUSSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 167
TABLE 158 RUSSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 167
TABLE 159 RUSSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 168
TABLE 160 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 168
TABLE 161 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 168
TABLE 162 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 169
TABLE 163 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 169
TABLE 164 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 169
TABLE 165 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 170
TABLE 166 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 171
TABLE 167 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 172
TABLE 168 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 173
TABLE 169 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 173
TABLE 170 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 173
TABLE 171 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 173
TABLE 172 SPAIN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 174
TABLE 173 SPAIN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 174
TABLE 174 SPAIN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 175
TABLE 175 SPAIN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 175
TABLE 176 SPAIN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 176
TABLE 177 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 176
TABLE 178 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 176
TABLE 179 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 177
TABLE 180 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 177
TABLE 181 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 177
TABLE 182 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 178
TABLE 183 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 179
TABLE 184 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 180
TABLE 185 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 181
TABLE 186 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 181
TABLE 187 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 181
TABLE 188 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 181
TABLE 189 TURKEY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 182
TABLE 190 TURKEY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 182
TABLE 191 TURKEY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 183
TABLE 192 TURKEY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 183
TABLE 193 TURKEY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 184
TABLE 194 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 184
TABLE 195 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 184
TABLE 196 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 185
TABLE 197 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 185
TABLE 198 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 185
TABLE 199 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 186
TABLE 200 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 187
TABLE 201 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 188
TABLE 202 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 189
TABLE 203 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 189
TABLE 204 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 189
TABLE 205 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 189
TABLE 206 NETHERLANDS VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 190
TABLE 207 NETHERLANDS RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 190
TABLE 208 NETHERLANDS SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 191
TABLE 209 NETHERLANDS HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 191
TABLE 210 NETHERLANDS OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 192
TABLE 211 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 192
TABLE 212 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 192
TABLE 213 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 193
TABLE 214 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 193
TABLE 215 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 193
TABLE 216 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 194
TABLE 217 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 195
TABLE 218 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 196
TABLE 219 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 197
TABLE 220 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 197
TABLE 221 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 197
TABLE 222 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 197
TABLE 223 SWITZERLAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 198
TABLE 224 SWITZERLAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 198
TABLE 225 SWITZERLAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 199
TABLE 226 SWITZERLAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 199
TABLE 227 SWITZERLAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 200
TABLE 228 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 200
TABLE 229 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 200
TABLE 230 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 201
TABLE 231 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 201
TABLE 232 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 201
TABLE 233 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 202
TABLE 234 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 203
TABLE 235 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 204
TABLE 236 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 205
TABLE 237 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 205
TABLE 238 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 205
TABLE 239 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 205
TABLE 240 BELGIUM VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 206
TABLE 241 BELGIUM RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 206
TABLE 242 BELGIUM SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 207
TABLE 243 BELGIUM HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 207
TABLE 244 BELGIUM OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 208
TABLE 245 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 208
TABLE 246 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 208
TABLE 247 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 209
TABLE 248 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 209
TABLE 249 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 209
TABLE 250 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 210
TABLE 251 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 211
TABLE 252 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 212
TABLE 253 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 213
TABLE 254 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 213
TABLE 255 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 213
TABLE 256 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 213
TABLE 257 HUNGARY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 214
TABLE 258 HUNGARY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 214
TABLE 259 HUNGARY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 215
TABLE 260 HUNGARY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 215
TABLE 261 HUNGARY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 216
TABLE 262 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 216
TABLE 263 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 216
TABLE 264 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 217
TABLE 265 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 217
TABLE 266 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 217
TABLE 267 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 218
TABLE 268 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 219
TABLE 269 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 220

LIST OF FIGURES

FIGURE 1 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 28
FIGURE 2 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: DATA TRIANGULATION 31
FIGURE 3 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: DROC ANALYSIS 32
FIGURE 4 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 33
FIGURE 5 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: COMPANY RESEARCH ANALYSIS 33
FIGURE 6 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS 34
FIGURE 7 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID 36
FIGURE 8 EUROPE PCR BASED INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID 38
FIGURE 9 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: VENDOR SHARE ANALYSIS 39
FIGURE 10 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 43
FIGURE 11 THE GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS IS DRIVING THE GROWTH OF THE EUROPE PCR-BASED INFECTIOUS DISEASE MARKET FROM 2024 TO 2031 44
FIGURE 12 THE INFECTION TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PCR-BASED INFECTIOUS DISEASE MARKET IN 2024 AND 2031 44
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PCR-BASED INFECTIOUS DISEASES MARKET 48
FIGURE 14 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2023 58
FIGURE 15 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2024-2031 (USD THOUSAND) 59
FIGURE 16 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, CAGR (2024-2031) 59
FIGURE 17 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, LIFELINE CURVE 60
FIGURE 18 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2023 76
FIGURE 19 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2024-2031 (USD THOUSAND) 77
FIGURE 20 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, CAGR (2024-2031) 77
FIGURE 21 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, LIFELINE CURVE 78
FIGURE 22 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2023 87
FIGURE 23 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2024-2031 (USD THOUSAND) 88
FIGURE 24 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, CAGR (2024-2031) 88
FIGURE 25 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, LIFELINE CURVE 89
FIGURE 26 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2023 94
FIGURE 27 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2024-2031 (USD THOUSAND) 95
FIGURE 28 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, CAGR (2024-2031) 95
FIGURE 29 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, LIFELINE CURVE 96
FIGURE 30 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2023 100
FIGURE 31 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2024-2031 (USD THOUSAND) 101
FIGURE 32 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, CAGR (2024-2031) 101
FIGURE 33 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, LIFELINE CURVE 102
FIGURE 34 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2023 106
FIGURE 35 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2024-2031 (USD THOUSAND) 107
FIGURE 36 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, CAGR (2024-2031) 107
FIGURE 37 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, LIFELINE CURVE 108
FIGURE 38 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2023 111
FIGURE 39 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2024-2031 (USD THOUSAND) 112
FIGURE 40 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, CAGR (2024-2031) 112
FIGURE 41 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, LIFELINE CURVE 113
FIGURE 42 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET: SNAPSHOT (2023) 119
FIGURE 43 EUROPE PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY SHARE 2023 (%) 221